# Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19

> **NCT05184127** · PHASE2 · COMPLETED · sponsor: **National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia** · enrollment: 156 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** MIR 19 ®
- **COMBINATION_PRODUCT:** Standard COVID-19 therapy

## Key facts

- **NCT ID:** NCT05184127
- **Lead sponsor:** National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-27
- **Primary completion:** 2021-09-07
- **Final completion:** 2021-09-07
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2022-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05184127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05184127, "Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05184127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*